Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Breast Neoplasms 3092Triple Negative Breast Neoplasms 504Ovarian Neoplasms 224Colorectal Neoplasms 189Carcinoma, Non-Small-Cell Lung 187Prostatic Neoplasms 180Neoplasms 171Lung Neoplasms 164Neoplasm Metastasis 159Melanoma 116Stomach Neoplasms 113Pancreatic Neoplasms 111Endometrial Neoplasms 105Uterine Cervical Neoplasms 93Squamous Cell Carcinoma of Head and Neck 87Head and Neck Neoplasms 81Colonic Neoplasms 81Carcinoma, Intraductal, Noninfiltrating 80Sarcoma 63Breast Carcinoma In Situ 61Carcinoma, Renal Cell 60Urinary Bladder Neoplasms 59Esophageal Neoplasms 58Motor Activity 57Brain Neoplasms 50Lymphedema 42Breast Cancer Female 40Advanced Breast Cancer 40Liver Neoplasms 39Gastrointestinal Neoplasms 38

Interventions

Leflunomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer × Breast × 1 year × Clear all
NCT04997993 2025-06-25

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 1 Recruiting
24 enrolled
BreastOther solid neoplasm

PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡